Skip to main content
. 2023 Jan 10;13:1083001. doi: 10.3389/fphar.2022.1083001

TABLE 4.

Adverse reactions and cases between the two groups.

Outcomes Trials Experimental group (events/total Control group (events/total Statistical method RR, 95%Cl I2 P
Erythra 3 2/167 4/166 REM 0.55 [0.11–2.60] 0 0.45
Headache 3 2/145 2/144 REM 0.99 [0.20–5.00] 0 0.99
Arrhythmia 3 0/92 3/92 REM 0.32 [0.05–2.09] 0 0.24
Dizziness 3 4/102 17/102 REM 0.24 [0.08–0.67] 0 0.007
Vomiting 2 5/92 10/92 REM 0.47 [0.15–1.44] 0 0.19
Nauseating 2 5/104 10/104 REM 0.47 [0.16–1.44] 0 0.19
Red face 1 1/20 0/20 - - - -
Chest tightness 1 0/55 1/55 - - - -
Chill 1 1/78 0/79 - - - -
Liver dysfunction 3 2/167 4/166 REM 0.55 [0.11–2.60] 0 0.45
Renal dysfunction 3 8/170 8/170 REM 1 [0.37–2.73] 0 1
Hypokalaemia 2 2/56 0/56 REM 3.12 [0.31–30.98] 0 0.33
Low blood pressure 3 1/109 4/108 REM 0.39 [0.07–2.03] 0 0.26